A deficient immune response to SARS-CoV-2 in the nasopharynx is associated with severe COVID-19 pneumonia

Objectives: We analyzed the expression of inflammatory and antiviral genes in the nasopharynx of SARSCoV-2 infected patients and their association with the severity of COVID-19 pneumonia. Methods: We conducted a cross-sectional study on 223 SARS-CoV-2 infected patients. Clinical data were collected from medical records, and nasopharyngeal samples were collected in the first 24 hours after admission to the emergency room. The gene expression of eight proinflammatory/antiviral genes (plasminogen activator urokinase receptor [ PLAUR ], interleukin [ IL ] -6, IL-8 , interferon [ IFN ] - & beta;, IFN-stimulated gene 15 [ ISG15 ], retinoic acid-inducible gene I [ RIG-I ], C-C motif ligand 5 [ CCL5 ], and chemokine C-XC motif ligand 10 [ CXCL10 ]) were quantified by real-time polymerase chain reaction. Outcome variables were: (i) pneumonia; (ii) severe pneumonia or acute respiratory distress syndrome. Statistical analysis was performed using multivariate logistic regression analyses. Results: We enrolled 84 mild, 88 moderate, and 51 severe/critical cases. High expression of PLAUR (adjusted odds ratio [aOR] = 1.25; P = 0.032, risk factor) and low expression of CXCL10 (aOR = 0.89; P = 0.048, protective factor) were associated with pneumonia. Furthermore, lower values of ISG15 (aOR = 0.88, P = 0.021), RIG-I (aOR = 0.87, P = 0.034), CCL5 (aOR = 0.73, P < 0.001), and CXCL10 (aOR = 0.84, P = 0.002) were risk factors for severe pneumonia/acute respiratory distress syndrome. Conclusion: An unbalanced early innate immune response to SARS-CoV-2 in the nasopharynx, characterized by high expression of PLAUR and low expression of antiviral genes ( ISG15 and RIG-I ), and chemokines ( CCL5 and CXCL10 ), was associated with COVID-19 severity. & COPY; 2023 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )